Valneva SE (VLA)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
€3.562
Buy
€3.60
€-0.138 (-3.73%)
Prices updated at 16 Dec 2025, 16:35 CET
| Prices minimum 15 mins delay
Prices in EUR
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers; one for the prevention of Japanese encephalitis (IXIARO) and the second (DUKORAL) for the prevention of cholera and diarrhoea.
-0.47%
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 154m | 170m | |
| 53m | 71m | |
| -82m | -78m | |
| -53.42 | -45.86 | |
| -101m | -12m | |
| -58m | 32m | |
| Sales, General and administrative | 97m | 95m |
| Interest expenses | 23m | 24m |
| Provision for income taxes | 3m | 761,000 |
| Operating expenses | 135m | 149m |
| Income before taxes | -99m | -11m |
| Net income available to common shareholders | -101m | -12m |
| -0.73 | -0.08 | |
| Net interest income | -22m | -22m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -0.73 | -0.08 |
| Free cash flow per share | -1.4993 | -1.1723 |
| Book value/share | 1.135 | 1.3391 |
| Debt equity ratio | 1.26208 | 1.064551 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 263m | 299m |
| Current liabilities | 159m | 115m |
| Total capital | 261m | 348m |
| Total debt | 209m | 216m |
| Total equity | 128m | 181m |
| Total non current liabilities | - | - |
| Loans | 133m | 167m |
| Total assets | 460m | 500m |
| Total liabilities | - | - |
| Cash and cash equivalents | 126m | 168m |
| Common stock | 139m | 162m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 287m | 126m |
| Cash dividends paid | - | - |
| -217m | -84m | |
| Investments (gains) losses | -21m | 77m |
| 126m | 168m | |
| Net income | - | - |
| -203m | -67m | |
| -14m | -16m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
